Drug Trial Radar · NCT05944978
A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies
Last checked: Nov 19, 2026Latest source record: Sep 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
3
Actual
Start
Aug 16, 2023
Primary completion
Dec 2025
Study completion Dec 2025
Sponsor
- Lead sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open-label, multicenter, phase Ib/II clinical trial was conducted to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of GNC-035 quad-specific antibody injection in patients with relapsed or refractory chronic lymphocytic leukemia and other hematological malignancies
Conditions
- Relapsed/Refractory Chronic Lymphocytic Leukemia
Interventions
GNC-035Drug
GNC-035 was intravenously infused 2h to 4h, once a week (IV, QW), and a 3-week cycle was used.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ib: Dose limiting toxicity (DLT)Time frame: Up to 21 days after the first dose
- Phase Ib: Maximum tolerated dose (MTD)Time frame: Up to 21 days after the first dose
- Phase Ib: Treatment-Emergent Adverse Event (TEAE)Time frame: Up to approximately 24 months
- Phase Ib: Recommended Phase II Dose (RP2D)Time frame: Up to 21 days after the first dose
- Phase II: Objective Response Rate (ORR)Time frame: Up to approximately 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.